(WASHINGTON) – The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, applauds the introduction of the Cancer Drug Coverage Parity Act in the U.S. House of Representatives by Representatives Brian Higgins (D-NY) and Peter King (R-NY). This important legislation would require private health plans offering intravenous (IV) chemotherapy benefits to plan subscribers to provide parity for orally administered and self-injectable anticancer chemotherapy medications, greatly reducing the financial burden that patients with blood and other cancers currently face in order to take these life-saving therapies.
While oral and patient-administered forms of chemotherapy have become more prevalent and represent the standard of care for many types of cancers for their convenience, efficacy, and low rate of side effects, they are covered differently than IV drugs, leaving many patients responsible for unsustainably high monthly co-payments. This legislation will help more patients afford these newer and more effective cancer therapies.
ASH supports oral anticancer drug parity legislation and will continue to work with Congress to identify supporters in the House and in the Senate, where the Society is advocating for a bipartisan companion bill.
While the Cancer Drug Coverage Parity Act will not solve the problem of high drug prices, it will help remove the high cost burden on some patients. By supporting this and other related legislative efforts, ASH remains committed to removing barriers to access to care and the heavy cost burdens on hematology patients.
Reporters who wish to arrange an interview with Dr. Abkowitz about ASH's position and action related to the Cancer Drug Coverage Parity Act should contact Andrea Slesinski at 202-552-4927 or firstname.lastname@example.org.
back to top